FDA OKs Merck’s heavyweight Keytruda for cancer niche — triggering title fight with the street brawlers at Regeneron
When Regeneron won its first OK for their PD-1 Libtayo as a treatment for recurrent or metastatic cutaneous squamous cell carcinoma, the second most …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
